Summary
The product WINSTROLAD 50 mg/ml, manufactured by Driada Medical, was subjected to independent laboratory testing to confirm its composition and dosage accuracy. The analysis, performed by Janoshik Analytical, identified the active ingredient as stanozolol with a measured concentration of 48.78 mg/ml, which is 2.44% below the labeled claim of 50 mg/ml. This minor variance indicates the product adheres closely to its label claim.
Testing commenced on 14 July 2022, with the sample received on 20 July 2022, and the analysis concluded on 21 July 2022. The product was submitted and funded by Driada Medical, warranting a balanced interpretation of the results.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: WINSTROLAD 50 mg/ml
- Active Ingredient: Stanozolol
- Batch Number: 277742
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #22174
- Testing Ordered: 14 July 2022
- Sample Received: 20 July 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 50 mg/ml (as stated on the label)
- Measured Concentration: 48.78 mg/ml
- Accuracy: 97.56% (2.44% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/22174_LP6DX53RFZFN
- Originally Published: https://thinksteroids.com/community/posts/2997048/
Evaluation of Manufacturer-Funded Testing
Given that the analysis was submitted and funded by Driada Medical, it is important to acknowledge potential conflicts of interest. However, the reputable analysis by Janoshik Analytical provides reassurance in the accuracy of the findings, with only a minor variance from the label claim.
Conclusion
The testing of WINSTROLAD 50 mg/ml confirms the presence of stanozolol at a concentration close to the labeled claim, with a minor deviation of 2.44%. This result demonstrates consistency in product quality, reinforcing its reliability for harm reduction purposes.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside independent results. Readers are encouraged to interpret this information responsibly.
